Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM (T2DM)

A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.

GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). The aims of this placebo controlled study are to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1070806 in obese subjects with Type 2 diabetes mellitus (T2DM), and to gain a better understanding of the mechanism by which GSK1070806 exerts its therapeutic effects.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus
• Intervention / Treatment: Biological: GSK1070806; Biological: GSK1070806; Other: Placebo (saline)

Detailed Description

The study will be a randomised, single-blind (sponsor-unblinded), placebo-controlled, study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous infusions (2 doses 4-weeks apart) of GSK1070806 in obese patients with T2DM. The primary objective of the study will be to assess improvements in fasting and postprandial glucose control. This will be a parallel-group study in 30 obese subjects with T2DM who are poorly controlled on metformin monotherapy (HbA1C>7% but <9.5%), and who have levels of microalbuminuria indicative of progressive kidney disease i.e. 30-300mg/L albumin in urine or ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤30mg/mmol. There will be three treatment groups comprising two active and one placebo arm with 10 subjects per dose group. The study contains a broad range of biomarker assessments, the purpose of which is to evaluate the mechanistic basis by which GSK1070806 exerts its therapeutic benefit in subjects with T2DM.

Subjects will be randomised into one of the three treatment groups where they will receive two intravenous infusions of GSK1070806 or placebo twenty-eight days apart. A MMT challenge will be conducted on Day 1, Day 29, Day 57 and Day 85 for evaluation of the primary endpoints.

• Study Type: Interventional
• Enrollment (Actual): 37
• Phase: Phase 2

Contacts and Locations

Study Locations

• Spain
  • Alicante, Spain, 03004
    • GSK Investigational Site
  • Alzira/Valencia, Spain, 46600
    • GSK Investigational Site
  • Granada, Spain, 18012
    • GSK Investigational Site
  • La Roca del Valles (Barcelona), Spain, 08430
    • GSK Investigational Site
  • Lleida, Spain, 25198
    • GSK Investigational Site
  • Madrid, Spain, 28046
    • GSK Investigational Site
  • Madrid, Spain, 28034
    • GSK Investigational Site
  • Malaga, Spain, 29010
    • GSK Investigational Site
  • Málaga, Spain, 29010
    • GSK Investigational Site
  • Petrer, Alicante, Spain, 03610
    • GSK Investigational Site
  • Santander, Spain, 39008
    • GSK Investigational Site
• United Kingdom
  • Cambridge, United Kingdom, CB2 2GG
    • GSK Investigational Site
  • Dundee, United Kingdom, DD1 9SY
    • GSK Investigational Site
  • Warwickshire
    • Birmingham, Warwickshire, United Kingdom, B15 2TT
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. A diagnosis of T2DM as determined by a responsible physician based on a medical evaluation including medical history, physical examination, and laboratory tests, with onset at least 6 months prior to Screening.
2. Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.
3. HbA1c levels ≥ 7.0 % and ≤ 9.5%; at Screening.
4. On a stable dose of monotherapy with metformin for three months prior to screening, and at a total daily dose greater than or equal to 1000 mg for at least 2 months prior to dosing.
5. Fasting plasma glucose level < 13.3 mmol/L (240 mg/dL) at screening.
6. Obese with BMI ≥ 30 kg/m2, and < 40 kg/m2.
7. Presence of microalbuminuria: 30-300mg/L albumin in urine or Albumin Creatinine Ratio (ACR) ≥ 3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤ 30 mg/mmol (female and male)..
8. The subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

9. A female subject is eligible to participate if she is of:

   • Non-childbearing potential
   • Child-bearing potential and agrees to use an acceptable form of contraception.
10. Male subjects must agree to use one of the contraception methods listed
11. ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
12. Single or Average QTc, QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.

Exclusion Criteria:

1. Current evidence, or history within the last 7 days, of an influenza-like illness as defined by fever (>38°C) and two or more of the following symptoms: cough, sore throat, runny nose, sneezing, limb / joint pain, headache, vomiting / diarrhoea in the absence of a known cause, other than influenza.
2. Use of anti-inflammatory drugs including corticosteroids, chronic maintenance therapy with NSAIDs, anti-Tumor Necrosis Factor (anti-TNF) or anti-Interleukin-1 (anti-IL1) within 60 days prior to dosing.
3. Current evidence of ongoing or acute infection, history of repeated, chronic or opportunistic infections (e.g. recurrent folliculitis, other cutaneous infections or repeated pneumonia) or history of a serious bacterial infection within 6 months of randomisation.
4. History of malignancy or significant cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions.
5. History chronic granulomatous infections, such as of Mycobacterium tuberculosis or any other previous Mycobacterium infection.
6. Creatinine clearance less than 60ml/min
7. Screens positive of Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV)
8. History of a severe allergic reaction, anaphylaxis or immunodeficiency.
9. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
10. A positive pre-study drug/alcohol screen.
11. History of regular alcohol consumption within 6 months of the study
12. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
13. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
14. Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
15. History of sensitivity to any of the study medications, or components thereof
16. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
17. Pregnant females as determined by positive serum or urine hCG test at screening.
18. Lactating females.
19. Unwillingness or inability to follow the procedures outlined in the protocol.
20. Subject is mentally or legally incapacitated.
21. Subject has received a live attenuated vaccine(s) within 30 days of randomisation or will require vaccination with a live attenuated vaccine prior to the end of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: GSK1070806 0.25mg/kg; TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart	Biological: GSK1070806; To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration; Biological: GSK1070806; To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
Active Comparator: GSK1070806 5mg/kg; Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart	Biological: GSK1070806; To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration; Biological: GSK1070806; To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
Placebo Comparator: Placebo (Saline); Two IV administrations of saline 4 weeks apart	Other: Placebo (saline); To compare the efficacy and biomarker changes between placebo and active groups

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT)	To evaluate the efficacy of two repeat intravenous dose administrations of GSK1070806 in subjects with T2DM	Up to 85 days after the first does

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability parameters include: adverse events, clinical laboratory tests, electrocardiograms (ECGs), and vital signs	To evaluate the safety and tolerability of two repeat intravenous dose administrations of GSK1070806 in obese subjects with T2DM	Up to 210 days after the first dose
Change from baseline in % HbA1c, fasting blood insulin, and C-peptide levels; change from baseline in weighted mean insulin, and C-peptide levels [AUC (0-4hrs)] post-MMT and derived measures of insulin sensitive	To evaluate the effect of two repeat intravenous dose administrations of GSK1070806 on additional markers of efficacy, in obese subjects with T2DM	Up to 85 days after the first dose
AUC(0-τ)	To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM	Up to 210 days after the first dose
Serum levels of free IL-18 and drug bound IL 18	To investigate the effect of repeat intravenous doses of GSK1070806 on free and drug bound IL 18 levels (if measurable) in obese subjects with T2DM.	Up to 210 days after the first dose
Change from baseline in serum and/or plasma levels of biomarkers of inflammation (e.g. hs-CRP, and IL-6) and metabolic disease (e.g. adiponectin, fructosamine, total cholesterol, high-density lipoprotein (HDL)/low-density lipoprotein (LDL), triglycerides	To explore the pharmacodynamic (PD) effect of repeat intravenous doses of GSK1070806 on biomarkers of inflammation and metabolic disease	Up to 85 days after the first dose
Change from baseline in waist circumference and BMI	To investigate the effect of repeat intravenous doses of GSK1070806 on body composition in obese subjects with T2DM	Up to 85 days after the first dose
Cmax	To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM	Up to 210 days after the first dose
Tmax	To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM	Up to 210 days after the first dose
after the second dose λz	To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM	Up to 210 days after the first dose
t1/2	To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM	Up to 210 days after the first dose

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• McKie EA, Reid JL, Mistry PC, DeWall SL, Abberley L, Ambery PD, Gil-Extremera B. A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus. PLoS One. 2016 Mar 1;11(3):e0150018. doi: 10.1371/journal.pone.0150018. eCollection 2016.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start: August 1, 2012
• Primary Completion (Actual): September 1, 2013
• Study Completion (Actual): January 1, 2014

Study Registration Dates

• First Submitted: July 12, 2012
• First Submitted That Met QC Criteria: July 19, 2012
• First Posted (Estimate): July 24, 2012

Study Record Updates

• Last Update Posted (Estimate): November 21, 2016
• Last Update Submitted That Met QC Criteria: November 18, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: Efficacy; Obese; T2DM; IL-18; Monoclonal antibody (mAb)
• Other Study ID Numbers: 116378

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Dataset Specification
   Information identifier: 116378
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Annotated Case Report Form
   Information identifier: 116378
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Study Protocol
   Information identifier: 116378
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Statistical Analysis Plan
   Information identifier: 116378
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Individual Participant Data Set
   Information identifier: 116378
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Informed Consent Form
   Information identifier: 116378
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Clinical Study Report
   Information identifier: 116378
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register